Read the newsletter by clicking here
At Xintela, we continue to work intensively to achieve milestones. We now have full focus on the preparation of the GMP (Good Manufacturing Practice) production of our stem cells and preparing for clinical trials in both horses and humans. At the end of May, we announced the signing of a Memorandum of Understanding agreement with the leading European cell therapy company, CO.DON, after successful validation of our quality assurance assay, XACT™. This shows that our technology platform is internationally competitive and that possibilities to secure new collaborative agreements on Xintela’s quality assurance biomarkers for cell therapy are very good. At the same time, we continue the work to identify partners for the glioblastoma project and our Antibody Drug Conjugate (ADC) therapy.
Recently, we were very pleased that Xintela, together with other players from Academia, healthcare and industry, received a large government investment to stimulate the development of cell and gene therapy in Sweden. We will explain more about this multimillion SEK investment later in this newsletter.
You can also read an interview with Xintela’s new Board Member, Keld Søndergaard, who brings with him valuable experience in finance and corporate development. Moreover, Thomas Areschoug tells us about the partnership conferences that we have participated in this summer, one in London in May and the large BIO Conference in the USA in June.
I would also like to take the opportunity to wish you all a lovely summer.
CEO, Xintela AB
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
BioStock was given the opportunity to interview Sven Kili in connection with his visit to Sweden for board and strategy work in Xintela.
Dr. Marcus Keep comments on Xintelas glioblastoma project.
Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.
Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.
In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.
See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.
See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).
See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.
Investor presentation from Lund - Jan 27
Interview with Xintelas CEO